Background {#Sec1}
==========

Currently, breast cancer is an increasing cause of cancer-induced deaths in the world \[[@CR1]\]. Multimodality treatment strategies have been proposed for eradicating breast cancer, but still, many patients with breast cancer are in multiple threats to their lives \[[@CR2]\]. The bone is the most vulnerable site for breast cancer metastasis. Bone microenvironment has a significant role in harboring disseminated tumor cells and a source of late relapse \[[@CR3]\]. Therefore, agents that affect bone metabolism might provide meaningful reductions in the risk of metastasis as well as prevent the development of bone lesions \[[@CR4]\]. Malignancy and cancer treatment-induced bone loss can make bone mineral reserves decrease, and patients would face risks of skeletal-related events (SREs) such as pathologic fracture and spinal cord compression \[[@CR3]\].

Breast cancer cells usually metastasize to the bone by secreting factors that enable tumor cells to be gathered inside of the bone tissues. Tumor cells produce cytokines that induce osteoclast formation and bone resorption such as interleukin-8 and parathyroid hormone-related protein \[[@CR2]\]. Osteoclast would increase both osteolysis and the release of tumor-promoting growth factors from the bone matrix. Using antiresorptive agents to cease osteolysis should make the bone microenvironment difficult for cancer stem cell survival and growth \[[@CR2]\].

In patients with bone metastases or multiple myeloma, bisphosphonates are part of the standard treatments \[[@CR2], [@CR5]\]. Bisphosphonates are analogs of inorganic pyrophosphates, commonly used for the management of metastatic bone disease such as breast cancer, prostate cancer, and multiple myeloma. Bisphosphonates are capable of localizing metastatic lesions and inhibiting osteoclastic function \[[@CR6]--[@CR8]\]. Because bisphosphonates bind strongly to exposed bone mineral around resorbing osteoclasts, high levels of bisphosphonate in the resorption lacunae would remain even after several years. Within the bone, bisphosphonates are not metabolized and these high concentrations will be held for long periods of time \[[@CR6]\]. Although whole mechanism of this bisphosphonate-related osteoclast inhibition has not been completely explained, it has been considered that these compounds affect bone turnover at various levels \[[@CR9]\]. On a cellular level, the bisphosphonates target the osteoclasts and may inhibit their function as follows: hindering the osteoclast recruitment; reducing the osteoclast life span \[[@CR10], [@CR11]\]. At a molecular level, it has been supposed that bisphosphonates regulate osteoclastic function by interacting with a cell surface receptor or an intracellular enzyme \[[@CR12]\]. About 300,000--500,000 cancer patients were prescribed intravenous (IV) bisphosphonates in 2004 \[[@CR13]\].

The metastatic breast cancer patients who need for bisphosphonate therapy should be relieved from the bone pain and hypercalcemia and improve quality of life \[[@CR6]\]. Bisphosphonate therapy has shown dramatic effect on reducing the risk of SREs by reducing this risk by nearly one third, and because of this reason, intravenous bisphosphonates are commonly used in the oncology practice \[[@CR14], [@CR15]\]. Zolendronate, the most potent bisphosphonate, is the second-generation bisphosphonate and approved for patients with metastatic breast cancer, multiple myeloma, hypercalcemia of malignancy, or Paget's disease of bone and for patients with documented bone metastases from any solid tumor (i.e., prostate cancer, lung cancer) \[[@CR6]\]. In comparison with other bisphosphonates, zolendronate is crucially more effective in reducing the risks of SREs and controlling hypercalcemia of malignancy \[[@CR16]\].

Bisphosphonate-related osteonecrosis of the jaw (BRONJ), first reported by Marx in 2003, is a rare but emerging complication associated with long-term use of bisphosphonates, especially pamidronate and zoledronate \[[@CR17]\]. The common symptoms of BRONJ are teeth mobility, swelling, bone dehiscence, chronic bone necrosis, and osteolytic radiographic features. The American Association of Oral and Maxillofacial Surgeons (AAOMS) proposed a staging system to suggest guidelines for prognosis and treatment of BRONJ (Table [1](#Tab1){ref-type="table"}) \[[@CR18]\]. There are several reports regarding breast cancer with jaw bone necrosis \[[@CR3], [@CR19]--[@CR21]\]; however, no case review has been reported in our country. In the present study, we tried to evaluate the BRONJ in breast cancer patients who were treated with intravenous BPs that whether conservative or surgical management worked on each stage.Table 1Staging of bisphosphonate-related osteonecrosis of the jawStagesDescriptionAt riskNo apparent necrotic bone in patients who have been treated with either oral or intravenous bisphosphonates.Stage 0There is no clinical evidence of necrotic bone, but there are nonspecific clinical findings and symptoms such as swelling of the soft tissue and fistula formation.Stage 1There is exposed and necrotic bone or fistulas that probes to the bone in asymptomatic patients but there is no evidence of infection.Stage 2There is exposed and necrotic bone or fistulas that probes to the bone associated with infection as evidenced by pain and erythema in the region of exposed bone with or without purulent drainage.Stage 3There is exposed and necrotic bone or a fistula that probes to the bone with pain, infection, and one or more of the following: exposed and necrotic bone extending beyond the region of alveolar bone resulting in (1) pathologic fracture, (2) extraoral fistula, (3) oral-antral/oral-nasal communication, or (4) osteolysis extending to the inferior border of the mandible or sinus floor.

Methods {#Sec2}
=======

A total of 25 female BRONJ patients who suffered from breast cancer with bone metastasis from January 2008 to November 2014 were included in this study. All patients had received zolendronate (Zometa**®**, Novatis, USA) for treating metastatic bone lesions. Average age was 55.4 years old (38--74). Twelve maxillae and 16 mandibles were involved. The diagnosis of BRONJ in these patients was based on the guidelines provided by the AAOMS position paper (Table [1](#Tab1){ref-type="table"}) \[[@CR18]\]. Staging of the breast cancer, duration of bisphosphonate usage, etiology of BRONJ, and treatment results were reviewed retrospectively. Conservative treatment with irrigation, antibiotic medication, analgesics, and oral gargle was applied for all patients for the initial treatment. Patients who had a sequestrum underwent debridement and primary closure. Because of the retrospective study with de-identification of the patient's data, institutional review board of our institution exempted ethical review of this study.

Results {#Sec3}
=======

Staging and treatment of breast cancer {#Sec4}
--------------------------------------

Staging of the breast cancer at initial visit, past treatment history about surgery, chemotherapy and radiation, and survival of breast cancer patients are summarized (Table [2](#Tab2){ref-type="table"}). The staging of breast cancer patients was based on the guidelines provided by American Joint Committee on Cancer (AJCC) staging manual (7th edition) \[[@CR22]\]. Survival period means the months from operation date or the day that biopsy proved malignant breast cancer when operation did not perform to the latest follow-up. According to AJCC cancer staging manual, two (8 %) were stage 1, eleven (44 %) were stage 2, three (12 %) were stage 3, and nine patients (36 %) were stage 4. Nine patients underwent chemotherapy without surgery. The mean follow-up period was 16.0 months (2--65 months) and mean survival period of patients was 96.2 (10--240). Three patients died of progression of metastasis during follow-up periods.Table 2Staging, treatment, and survival of metastatic breast cancer patientsCase numberAgeSexStageOperation (Y/N)Chemotherapy (Y/N)Survival (Y/N)Survival period (months)145FIIAYYY118253FIVNYY36358FICYNY105455FIIBYYY76570FIIAYYY240659FIIBYYY39767FIVNYY104850FIIAYNY139961FIVNYN421051FIIIAYYY1491155FIVNYY441252FIVNYY641367FIIIAYYY931438FIIICYYN1321565FIIBYYY1751649FIVNYN191749FIIBYYY1241848FIIAYYY1351970FIIAYYY1502042FIVNYY102149FIIAYYY942248FIIAYYY1242355FIVNYY232454FIVNYY862574FIAYYY85*F* female, survival period means the months from operation date or the day that biopsy proved malignant breast cancer when operation did not perform to the last follow-up

Clinical features and medical history {#Sec5}
-------------------------------------

Initial symptoms were pain in sixteen patients (64 %), swelling in seven (28 %), pus discharge in eight (32 %), tooth mobility in two (8 %), unhealed operation site in three (12 %), intraoral fistula in one (4 %), while multiple symptoms were observed in individuals (Table [3](#Tab3){ref-type="table"}). Mandible was involved in 16 patients and maxilla in 12 patients. Three patients were affected both mandible and maxilla. The etiologies for BRONJ were mainly tooth extraction in nineteen patients (76 %), dental implant in two (8 %), endodontic treatment in one (4 %), and spontaneously occurred in three patients (12 %). Based on the BRONJ classifications of AAOMS position paper, one patient (4 %) was stage 3, sixteen (64 %) were stage 2, one (4 %) was stage 1, and six (24 %) were stage 0. All of the patients had received intravenous bisphosphonate therapy with 4 mg of zolendronate every month. Mean number of Zometa**®** injection was 32.7 (3--114) times. In the aspect of comorbidity, 3 of 25 patients were affected by diabetes mellitus and 4 were affected by hypertension.Table 3Clinical features and bisphosphonate history of patientsCase numberAgeSexChief complaintLocationTrigger eventStageBP therapyDoseInjection timesComorbid disease145FItching sensationMaxillaExtraction1Zolendronate4 mg/monthly44-253FPain, swellingMaxillaExtraction2Zolendronate4 mg/monthly41Hypertension358FPain, SwellingMandibleEndo2Zolendronate4 mg/monthly3-455FSwelling, unhealing extraction socketMandibleExtraction0Zolendronate4 mg/monthly7-570FPain, swelling, pus dischargeMandibleImplant2Zolendronate4 mg/monthly18Diabetes mellitus, hypertension659FPain, pus dischargeMaxillaExtraction2Zolendronate4 mg/monthly20Hypertension767FPain, pus dischargeMaxillaExtraction0Zolendronate4 mg/monthly24Hypertension850FPus discharge, unhealing implantation siteMandibleImplant0Zolendronate4 mg/monthly114-961FPain, swelling, pathologic fractureMandibleExtraction3Zolendronate4 mg/monthly7Diabetes mellitus1051FPainMaxillaExtraction2Zolendronate4 mg/monthly49Diabetes mellitus1155FPainMandibleExtraction2Zolendronate4 mg/monthly14-1252FTooth mobilityMandibleExtraction0Zolendronate4 mg/monthly67-1367FPain, tooth mobilityBilateral mandibleExtraction2Zolendronate4 mg/monthly20-1438FPus dischargeMaxillaExtraction2Zolendronate4 mg/monthly21-1565FPus dischargeMaxillaExtraction2Zolendronate4 mg/monthly23-1649FPus dischargeMandibleExtraction0Zolendronate4 mg/monthly13Hypothyroidism1749FPainMandibleExtraction2Zolendronate4 mg/monthly58-1848FPain, swellingMaxilla and mandibleExtraction2Zolendronate4 mg/monthly47-1970FPain, unhealing\
extraction socketBilateral maxilla and mandibleExtraction2Zolendronate4 mg/monthly52-2042FPus dischargeMaxilla and mandibleExtraction2Zolendronate4 mg/monthly40-2149FPainMaxillaSpontaneous0Zolendronate4 mg/monthly9-2248FPain, pus dischargeMandibleExtraction2Zolendronate4 mg/monthly43-2355FPainMandibleSpontaneous2Zolendronate4 mg/monthly10-2454FPainMaxillaExtraction2Zolendronate4 mg/monthly48-2574FSwelling, intraoral fistulaMandibleSpontaneous2Zolendronate4 mg/monthly25-*F* female

Treatment and outcome for BRONJ {#Sec6}
-------------------------------

All 25 patients were treated conservatively with antibiotics, chlorohexidine gargle, and analgesics at the time of initial visit. Surgical treatment was performed in 21 patients (Table [4](#Tab4){ref-type="table"}). Most of the patients required sequestrectomy and saucerization. Two patients underwent simple curettage and one underwent dental implant fixture removal. Four patients (16 %) were managed by conservative treatment solely. When BRONJ was diagnosed, patient had been recommended to stop administration of zolendronate except one who suffered from bone metastasis on mandible (No. 12 patient). Systemic condition and intraoral and extraoral characteristics were assessed in collaboration with medical oncologists. A surgical approach was considered after 3 months of bisphosphonate discontinuation in patients with chronic symptoms. In this study, surgical treatment was performed in 21 patients (84 %) with success in 18 patients. Three patients showed repeated bone exposure and infection after initial operation. Healing of the oral mucosa was observed in 19 patients (76 %) with no other signs.Table 4Treatment and outcome of patientsCase numberAgeSexSurgical treatmentFollow-up (M)BP discontinuationOutcome145FSequestrectomy19YesHealed mucosa253FSequestrectomy5YesHealed mucosa358FSequestrectomy12YesAnother bony exposure (Mx), death455FConservative management12YesHealed mucosa570FSequestrectomy65YesHealed mucosa659FConservative management2YesNo more follow-up with unhealed state767FCurettage12YesHealed mucosa850FImplant removal17YesBony exposure961FSegmental mandibulectomy36YesDeath1051FSequestrectomy18YesHealed mucosa1155FSequestrectomy25YesHealed mucosa1252FConservative management19NoMandible metastasis, skin fistula1367FSequestrectomy11YesHealed mucosa1438FSequestrectomy6YesHealed mucosa, death1565FSequestrectomy9YesHealed mucosa1649FCurettage2YesNo more follow-up with healed state1749FSequestrectomy35YesHealed mucosa and skin1848FSequestrectomy6YesBony exposure1970FSequestrectomy21YesHealed mucosa2042FSequestrectomy10YesHealed mucosa2149FConservative management10YesHealed mucosa2248FSequestrectomy4YesHealed mucosa2355FSequestrectomy13YesHealed mucosa2454FSequestrectomy17YesHealed mucosa2574FSequestrectomy14YesHealed mucosa*F* female, *BP* bisphosphonate, *M* month, *Mx* maxilla

Case review {#Sec7}
-----------

In September 2014, number 2 patient was referred from the Department of Oncology for maxillary bone pain and gingival swelling after extraction of the right maxillary premolar. Her stage of breast cancer was IV, and she had received chemotherapy for palliative treatment. She had received intravenous bisphosphonate for more than 3 years and had hypertension for comorbidity. Necrotic bone was observed on the buccal side of right upper premolars. After a month of conservative therapy, she underwent sequestrectomy and primary closure with buccal fat graft. Inflamed mucosa and necrotic sequestrum had been treated and all of the clinical symptoms were improved (Fig. [1a](#Fig1){ref-type="fig"}--[d](#Fig1){ref-type="fig"}).Fig. 1Clinical, panoramic examinations of patient (No. 2 patient). **a** Exposed maxillary bone in the buccal side of second premolar. **b** Initial panoramic view showing bone destruction in the right maxillary premolar area with unhealed extraction socket. **c** Intraoral photograph showing healed mucosa 4 months postoperation. **d** Panoramic view showing bone defect in right maxillary premolar area 4 months postoperation

Number 12 patient was referred from the Department of Oncology complaining of tooth mobility during chemotherapy. Her stage of breast cancer was also IV, and she did not undergo operation because of multiple bone metastases. She had received chemotherapy for palliative treatment. She had received intravenous bisphosphonates for more than 5 years. According to the bone scan image, hot uptake was found in the anterior mandible which resembled bone metastasis. For differential diagnosis, biopsy was performed before operation resulting in osteomyelitis with bacterial contamination. During conservative treatment, she reported skin fistula and necrotic bone exposure in oral cavity. Due to fast progression of the metastasis, no surgical exploration was performed (Fig. [2a](#Fig2){ref-type="fig"}--[d](#Fig2){ref-type="fig"}).Fig. 2Clinical, panoramic, and bone scan examinations of patient (No. 12 patient). **a** Clinical photograph of exposed mandible. **b** Panoramic image during conservative treatment. **c** Extraoral fistula formation with pus discharge in the right submental area. **d** Bone scan image showing hot uptake in the anterior mandible

Number 22 patient was referred from the Department of Oncology for mandible bone pain and pus discharge on the left lower molar area where extraction had been performed in previous dental clinic. Her stage of breast cancer was IIA, and she underwent operation. She had been treated with intravenous bisphosphonate for more than 3 years after realizing bone metastasis. Sequestrum was observed on panoramic view. For surgical debridement, bisphosphonate was discontinued for 2 months before operation. After surgery, progression of BRONJ ceased without pain and swelling. Two months postoperation, cortical margin around operation site was distinct in panoramic view (Fig. [3a](#Fig3){ref-type="fig"}--[d](#Fig3){ref-type="fig"}).Fig. 3Clinical, panoramic examinations of patient (No. 22 patient). **a** Intraoral photograph showing inflamed mucosa with swelling. **b** Panoramic view showing sequestrum in the left posterior mandible. **c** Intraoral photograph showing healed mucosa 2 months postoperation. **d** Panoramic view showing cortical bone healing and resection of sequestrum 2 months postoperation

Discussion {#Sec8}
==========

It has been reported that the incidence of BRONJ with intravenous bisphosphonates is more frequent than that with oral bisphosphonates \[[@CR23]\]. The incidence of BRONJ with intravenous bisphosphonates has been reported 0.8--1.2 % on average, increasing up to 21 % after injection of bisphosphonate for 3 years or more \[[@CR5], [@CR24], [@CR25]\]. Bisphosphonates bind to bone hydroxyapatite for almost 10 years, and because of this reason, discontinuation of bisphosphonate administration before dental treatment is still disputable \[[@CR26]\]. Cancer patients who have high risks for bone pain, hypercalcemia, or pathological fracture could effectively benefit from intravenous bisphosphonates. However, BRONJ could happen during treatment \[[@CR3], [@CR19]--[@CR21]\]. When BRONJ is suspicious, it is highly recommended to stop using them. In this study, 24 patients stopped taking bisphosphonates after consulting with an oncologist. However, it could not be discontinued in one patient who had suffered from multiple bone metastases with hypercalcemia.

The relatively high percentage of the maxilla (12 of 25 patients) involvement of BRONJ in this study is uncommon because the maxilla is provided with rich vascular supply. This finding is distinguished from other studies which reported dominant involvement of the mandible \[[@CR27]--[@CR30]\]. It may be related to the mechanism by which bisphosphonates would not only inhibit the angiogenesis but also affect in other way \[[@CR18]\]. One of the most frequent initiations of BRONJ is a dental extraction. In our case series, dental extraction was more frequent in the maxilla than the mandible.

The potent inhibition of osteoclast proceeds to reduce bone resorption and interrupt normal bone turnover remodeling, resulting in reduction of some mechanical properties in skeletal health \[[@CR31]\]. As bone resorption occurs, cytokines and growth factors would be released into the surrounding matrixes that are significant for regulating new bone development. The inhibition of new bone formation would lead to degrade bone quality during growth and fracture healing \[[@CR6]\]. Systemic conditions of patients involving diabetes mellitus or coagulopathy have also been reported as a risk factor for BRONJ \[[@CR18], [@CR32]\]. In the present study, three of the patients had diabetes mellitus.

Bisphosphonate therapy should be delayed until all necessary dental treatments have been performed, except life-threatening hypercalcemia \[[@CR18]\]. In this report, dental extraction was the most common etiology for BRONJ initiation. Other surgical procedures such as dental implant surgery and preprosthetic surgical treatment could be the causes of BRONJ \[[@CR33]\]. During bisphosphonate therapy, patients should manage their oral hygiene. Invasive dental procedures should be avoided during bisphosphonate therapy, if that is possible. Bacterial infection was observed in all the present cases, therefore, antibiotic treatment should be ensured on BRONJ patients \[[@CR23]\].

Recent studies have reported that surgical debridement might have benefited in eradicating necrotic bone in comparison with conservative treatment \[[@CR27], [@CR34]--[@CR36]\]. If invasive dental procedure is determined, a systemic perioperative antibiotic treatment is recommended. Surgical debridement should be done for those patients who complained symptoms. Obtaining a surgical margin with viable bleeding the bone is significant in surgery, and primary closure for wound healing should be served by using mucosal flaps for bone coverage \[[@CR3]\]. It is recommended that bisphosphonate administration should be withheld for 6--8 weeks before and after dental procedures \[[@CR3], [@CR18]\]. After complete wound healing is achieved, bisphosphonate therapy could be reinitiated because the risk of SREs would still exist and increase during the course of disease \[[@CR37]\]. Despite the several efforts for setting guidelines, the optimum treatment for BRONJ remains unclarified. It is necessary to accumulate further clinical data to make the standard for effective treatment in BRONJ patients.

Conclusions {#Sec9}
===========

Prevention of the BRONJ is critical in metastatic breast cancer patients. Dental extraction is the main etiology for BRONJ. Conservative treatment to reduce pain, discomfort, and infection is recommended for the initial therapy. However, if there is a sequestrum which is separated from the basal bone of the jaw, surgical debridement and primary closure is the key to treat the BRONJ.
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